H0847 creates the Expedited DNA Testing Grant Program within the Florida Department of Law Enforcement. The program is designed to award annual grants to law enforcement agencies so they can send evidentiary items for DNA testing to private laboratories when needed. The bill defines “private laboratory” as a DNA lab accredited for at least five years under ISO/IEC 17025:2017 and applicable FBI Quality Assurance Standards.
The grants may be used in two main situations: when the necessary technology or technique is not readily available at a local or state laboratory, or when the agency determines expedited testing would best advance an investigation. Each grant recipient must submit a report within one year detailing the amount of funding received, the number of cases tested, the type of DNA testing used, the private lab used, the primary equipment used, the lab report results, and the average turnaround time. The department is also authorized to adopt rules to administer the program and allocate funds. The act takes effect July 1, 2025.
Impact
The bill adds a new section, s. 943.328, Florida Statutes, and creates a new state grant program focused on forensic DNA testing. It does not change criminal procedure directly, but it gives law enforcement agencies a state-funded mechanism to outsource DNA analysis to qualified private labs in limited circumstances. The measure also imposes reporting obligations on grant recipients and gives FDLE rulemaking authority to manage the program and distribution of appropriated funds.
Sentiment
The overall sentiment appears strongly supportive. The bill passed the House Criminal Justice Subcommittee unanimously, passed the House Judiciary Committee with only one dissenting vote, and then passed both chambers overwhelmingly or unanimously on third reading. The vote pattern suggests broad bipartisan agreement that faster DNA testing can help investigations and improve case processing.
Contention
There was little visible contention in the available record. The only recorded opposition came in the House Judiciary Committee, where the bill received one no vote, but no transcript is available to show the specific concern. Potential areas of concern implied by the bill’s structure could include the use of public funds for private laboratory testing, the scope of agency discretion in deciding when expedited testing is warranted, and the administrative burden of reporting and rulemaking, but these issues were not reflected in any documented debate here.